Roche and Exiqon have agreed to jointly market Roche Applied Science's RealTime ready custom quantitative PCR assays with Exiqon's miRcury LNA Universal RT microRNA qPCR system, the companies said this week.

The co-marketing agreement builds on a licensing agreement related to the same technologies that has been in place since at least 2005, when Roche licensed Exiqon's locked nucleic acid technology to manufacture qPCR assays based on its universal probe library.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.